

May 5, 2025

**RE: LD 1847, An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products Similar to Adult Use Cannabis and Cannabis Products, Dedicate a Portion of the Adult Use Cannabis Sales and Excise Tax to Medical Use Cannabis Programs and Create a Study Group**

Senator Hickman, Representative Supica, and Members of the Joint Standing Committee on Veterans and Legal Affairs:

My name is Jennifer McGrath and I am writing today in strong opposition to LD 1847. As the spouse of a caregiver deeply involved in Maine's medical cannabis program, I am gravely concerned about the harmful impact this bill would have on patients, caregivers, and small businesses across our state.

LD 1847 proposes sweeping changes that would significantly increase the cost and complexity of compliance for medical cannabis providers. These changes disproportionately benefit large, multi-state operators with the resources to absorb new administrative burdens, while placing unsustainable pressure on locally owned small businesses—many of which are already struggling with rising costs and regulatory uncertainty.

**Section 12: Opposition to Mandatory Tracking Systems**

I am particularly opposed to Section 12, which would mandate the use of an electronic tracking system for medical cannabis. While tracking may have a place in the adult-use market, applying the same system to medical cannabis is both inappropriate and dangerous.

These systems require individuals to disclose sensitive personal information, including names, vehicle descriptions, license plates, delivery contents, and even travel routes. This level of surveillance creates serious safety risks for caregivers and delivery drivers, who could become targets for theft or violence. We currently take extensive precautions to avoid predictable routes or publicizing transport details—practices that would be undermined by this mandate.

Moreover, there is little confidence in the cybersecurity of these systems. A breach could expose private data not only about caregivers, but potentially also about patients who rely on this medicine for chronic and life-threatening conditions. The risk to personal safety and privacy is simply too great.

The current Trip Ticket system, administered by the Office of Cannabis Policy, already provides a reliable and secure method for documenting the transport of medical cannabis.

It ensures accountability and traceability without compromising safety or privacy. In fact, many of us in the industry have worked collaboratively with the Office to suggest improvements to the Trip Ticket process, demonstrating our commitment to transparency and compliance.

## **Conclusion**

LD 1847, and particularly Section 12, would impose unnecessary and dangerous burdens on Maine's medical cannabis community. I urge you to consider the real-world consequences of these proposals—not just for businesses, but for the patients who depend on us for safe, affordable access to their medicine.

Please vote **no** on LD 1847.

Thank you for your time and consideration.

Sincerely,  
Jennifer McGrath  
Saco